BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins. It is a cutting-edge and mature solution for oral formulations not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies.

Products, services, technology

Key products for outlicensing are sublingual products as exenatide, liraglutide, insulin+, and low dose sublingual IL2 for auto-immune disorders

Cooperation possibilities

BioLingus is open to partner its platform technology for development of products with other companies (eg peptides)

Location

Grossmatt 6, 6052 Hergiswil, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2014

  • Number of employees in Switzerland

    1-9